Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Clinical Disease Manifestations Associated With Tumor Necrosis Factor Inhibitor Nonresponse in Juvenile Spondyloarthritis. Local targets link to admitted publications; unresolved targets remain external evidence.
International League of Associations for Rheumatology classification of juvenile idiopathic arthritis, second revision, Edmonton, 2001
2004 · External reference
2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis
10.1002/art.40884 · 2019 · External reference
Survey of current practices in the management of anti-TNF failure in juvenile spondyloarthritis
2022 · External reference
10.1002/art.22181
10.1002/art.22181 · External reference
10.1136/annrheumdis-2014-205372
10.1136/annrheumdis-2014-205372 · External reference
10.1136/rmdopen-2016-000366
10.1136/rmdopen-2016-000366 · External reference
Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience
10.1093/rheumatology/keaa118 · 2020 · External reference
10.3899/jrheum.120602
10.3899/jrheum.120602 · External reference
10.1136/annrheumdis-2014-206034
10.1136/annrheumdis-2014-206034 · External reference
Enthesitis related arthritis in a longitudinal Southeast Asian registry: high prevalence of HLA-B27, different sacroiliitis risk factors and less common drug-free remission
10.3390/jcm10040568 · 2021 · External reference
Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children’s Health, Russia
10.1186/s12969-017-0178-9 · 2017 · External reference
Predicting probability of response to tumor necrosis factor inhibitors for individual patients with ankylosing spondylitis
10.1001/jamanetworkopen.2022.2312 · 2022 · External reference
10.3899/jrheum.120642
10.3899/jrheum.120642 · External reference
The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months
10.1186/s12969-017-0160-6 · 2017 · External reference
10.1002/art.1780371209
10.1002/art.1780371209 · External reference
10.1001/jama.2011.1671
10.1001/jama.2011.1671 · External reference
10.1136/ard.2006.054098
10.1136/ard.2006.054098 · External reference
Pharmacokinetics of subcutaneous methotrexate
10.1200/jco.1988.6.12.1882 · 1988 · External reference
10.1136/annrheumdis-2019-215427
10.1136/annrheumdis-2019-215427 · External reference
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study
10.1016/s2468-1253(19)30012-3 · 2019 · External reference
Effect of overweight and obesity on the response to anti-TNF therapy and disease course in children with IBD
10.1093/ibd/izae165 · 2025 · External reference
Associations between obesity and the effectiveness of anti–tumor necrosis factor-α agents in inflammatory bowel disease patients: a literature review and meta-analysis
10.1177/1060028019900660 · 2020 · External reference
The effect of adiposity on anti–tumor necrosis factor-alpha levels and loss of response in Crohn’s disease patients
10.14309/ctg.0000000000000233 · 2020 · External reference
High body mass index and response to anti-tumor necrosis factor therapy in pediatric Crohn’s disease
10.14309/ajg.0000000000002741 · 2024 · External reference
